Inflammation is a potentially blinding disorder that characterizes many intraocular diseases. Uveitis and conjunctivitis have been recognized as the representative inflammatory ocular diseases; but in recent years, inflammation is speculated to be involved in many other ocular diseases such as dry eye, glaucoma, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinopathy of prematurity, Grave’s ophthalmopathy (thyroid-associated orbitopathy), and orbital tumors. The correct diagnosis of inflammatory ocular diseases in daily practice remains complicated and challenging due to the lack of specific diagnostic biomarkers.
Biomarkers provide useful information in guiding clinical decision making in patients with inflammatory ocular diseases. There are a huge number of inflammatory ocular disease-related biomarkers in the literature, but only a few of biomarkers have been validated for clinical use. Novel approaches to biomarker discovery and validation are required for further progress to be made.
Omics technologies are a particularly promising example of novel approaches that can support the identification of novel biomarkers in inflammatory ocular diseases. Various methodologies can be used for this purpose. These investigations may involve tumor tissue, adjacent stromal tissue, ocular fluids, and blood samples.
For this Research Topic, we want to collect original research article and state-of-the-art reviews on novel or established genomic, proteomic, transcriptomic or metabolomic biomarkers, aiming to elucidate the pathophysiology of inflammatory ocular diseases as well as to identify new diagnostic biomarker or therapeutic targets.
Inflammation is a potentially blinding disorder that characterizes many intraocular diseases. Uveitis and conjunctivitis have been recognized as the representative inflammatory ocular diseases; but in recent years, inflammation is speculated to be involved in many other ocular diseases such as dry eye, glaucoma, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinopathy of prematurity, Grave’s ophthalmopathy (thyroid-associated orbitopathy), and orbital tumors. The correct diagnosis of inflammatory ocular diseases in daily practice remains complicated and challenging due to the lack of specific diagnostic biomarkers.
Biomarkers provide useful information in guiding clinical decision making in patients with inflammatory ocular diseases. There are a huge number of inflammatory ocular disease-related biomarkers in the literature, but only a few of biomarkers have been validated for clinical use. Novel approaches to biomarker discovery and validation are required for further progress to be made.
Omics technologies are a particularly promising example of novel approaches that can support the identification of novel biomarkers in inflammatory ocular diseases. Various methodologies can be used for this purpose. These investigations may involve tumor tissue, adjacent stromal tissue, ocular fluids, and blood samples.
For this Research Topic, we want to collect original research article and state-of-the-art reviews on novel or established genomic, proteomic, transcriptomic or metabolomic biomarkers, aiming to elucidate the pathophysiology of inflammatory ocular diseases as well as to identify new diagnostic biomarker or therapeutic targets.
